RxDoctor Payments Data

Melissa Piliang, MD

Dermatopathology · Cleveland, OHNPI 1487750444

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $84,063 of the $123,002 with a category attached, or 68.3%. 6 manufacturers reported payments, led by Pfizer at 58.4% of the total. Reporting peaked in 2023 at $59,469 and has fallen 72.2% since, to $16,540 in 2025. Among dermatopathology clinicians in OH with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$123,002in general payments, 2019–2025

Across 89 payments — averaging $1382.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$72K
  • Lilly USA, LLC$39K
  • Eli Lilly$11K
  • Sun Pharmaceutical Industries Inc.$817
  • Sanofi$118
  • Organogenesis Inc.$20
$145,395in research payments, 2019–2025

Across 36 payments — averaging $4038.76 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • AbbVie$96K
  • Sanofi US Services Inc.$38K
  • Pfizer$11K

What the payments were for

  • Consulting fees$26,97522%
  • Speaking & faculty fees$84,06368%
  • Travel & lodging$9,9528%
  • Food & beverage$1,8772%
  • Education$1350%

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Pfizer32$71,861
Lilly USA, LLC46$39,500
Eli Lilly7$10,685
Sun Pharmaceutical Industries Inc.2$817
Sanofi1$118
Organogenesis Inc.1$20

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$123,002 in reported general payments places this provider in the 95th percentile of 25 dermatopathology providers in Ohio.

See all dermatopathology providers in Ohio

Medicare billing

Part B allowed, 2024
$98,171
Medicare patients
1,375
Services billed
2,536

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Minoxidil53$627
Finasteride24$488
Ketoconazole30$371

Paid to pharmacies, not to this prescriber.

Other dermatopathology in Cleveland

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →